Occuity

04/03/2026

We’ve just published a short write-up about our experience at 100% Optical this weekend and it’s safe to say the momentum around AX1 is building.

The level of interest in the device from academia, independents and large groups was remarkable. What stood out most was how quickly optometrists were able to pick up the AX1 and start measuring axial length. In many cases, people were taking repeatable measurements within seconds of using the device for the first time.

That ease of use really matters.

Over the last few years there has been a clear shift in optometry. Myopia management is no longer something discussed occasionally - it’s increasingly recognised as part of a practitioner’s duty of care. Many more ECPs are now offering spectacle and contact lens solutions than ever before.

But many are still doing this without measuring axial length.

We heard the same challenges repeatedly:

• Existing systems are expensive
• Desktop devices take up valuable practice space
• Equipment gets tied up in testing rooms

So the idea of a handheld, fast, easy-to-use axial length device that fits into everyday workflows clearly resonated.

We also had some fun running the AX1 Scan Challenge at the stand. We found axial lengths ranging from 20.85 mm to 29.5 mm, and the fastest person scanned both of my (very long!) eyes in just 45 seconds — within minutes of picking up the device.

It really does feel like an exciting time for Occuity.

You can read the full recap here:
https://zurl.co/JCyiy

And if you missed us at the show but want to register interest in AX1, you can do that here:
https://zurl.co/BAIPB

This weekend Occuity was delighted to attend the UK's largest Optical tradeshow - 100% Optical - with our UK Distributor, Birmingham Optical. And I have to say, the level of interest in Occuity’s technology was striking.

03/03/2026

We’re proud to share that Occuity has been named Innovator of the Year at the Thames Valley Business & Community Awards.

It’s always encouraging when the work you’re immersed in every day is recognised externally. The judges highlighted our non-invasive optical technology, our focus on precision and research excellence, and the real-world clinical impact we are striving to deliver. That means a lot to the whole team.

This award reflects the effort of an incredible group of engineers, regulatory and compliance specialists, quality teams, clinical collaborators and commercial colleagues who work tirelessly to turn complex science into practical, usable healthcare solutions.

A special mention as well to our CEO, Dan Daly who was shortlisted for Entrepreneur of the Year. Building a regulated MedTech company is not for the faint-hearted, and that recognition is well deserved.

Our COO Mark Jenkins and COO Sharon Branch proudly collected the award on behalf of the team.

As regional winners, we now go through to the national finals of the Great British Business & Community Awards in September. We’re looking forward to representing the Thames Valley on the national stage.

Read More: https://zurl.co/ejD1I

24/02/2026

If you’re heading to 100% Optical this weekend, it’s well worth stopping by to see Occuity on Birmingham Optical - The Optical Company - Stand L30!

We’re running the AX1 Speed Scan Challenge, giving visitors the chance to experience fast, non-contact axial length measurement and see just how intuitive the AX1 is in real clinical hands. No Chin rests. No contact. Just a quick scan and clear data.

Axial length is becoming central to how we think about myopia management and long-term eye health. If you’re curious about axial length, myopia control, or where ocular biometry is heading next, come and have a go. Sometimes the best way to understand new technology is simply to sit down and try it.

See you at 100% Optical.

05/02/2026

🚀 We’re bringing the AX1 to 100% Optical - and we're inviting you to take part in the "AX1 Speed Scan Challenge".

Visit us on stand L30 with Birmingham Optical.

✔ Try the AX1
✔ 3 x £1,000 cashback Prizes to be won*
✔ Get priority access on release

19/12/2025

Today is the final day of our Republic crowdfunding campaign, so we thought we'd highlight what we said at the beginning & give you five simple reasons why we believe you should invest in Occuity:

- We’re developing technology that can genuinely change lives, using the eye as a window to the health of the body
- We’ve built a patented, non-contact optical platform that underpins multiple current & future devices
- We have an experienced leadership team with deep expertise in optics, engineering & MedTech
- We’re already generating revenue with the PM1, with major growth ahead through the AX1 & beyond
- We’re not a single-product company, but a scalable platform business with a clear roadmap into Oculomics, diabetes and systemic disease screening

If you’ve been watching the campaign and weighing it up, this really is your last chance to join us before the round closes and we move towards our next phase of growth.

Thanks again to everyone who has supported Occuity so far.

18/12/2025

We’re proud to share that Occuity has been featured in Ingenia magazine, the oyal Academy of Engineering’s , quarterly publication showcasing inspiring engineering stories from across the UK.

Ingenia highlights innovative technologies that are shaping the future, and we’re delighted that our work using the eye as a window into wider health has been chosen as an example of how engineering can open up new possibilities in healthcare.

Being featured in such a respected and prestigious publication is a real endorsement of the originality and potential of Occuity’s technology, and we’re pleased to see our approach recognised alongside other groundbreaking engineering innovations.

You can read the full article here: https://zurl.co/YQsAC

16/12/2025

We often say that Occuity is best understood in person.

Our technology platform is powerful, but it naturally raises questions. Seeing it being developed, meeting the team building it, and understanding how everything fits together makes a real difference. That’s why we regularly welcome potential investors to our HQ in Reading to show them first-hand what we’re building and how their investment is being put to work.

In this short video, Richard Kadri-Langford, our Head of Marketing recorded a simple walkthrough of our offices while our CEO, Dr. Dan Daly, talks through who we are, what we do, and how the team operates day to day. It was filmed in a single take to give an authentic, unfiltered view of Occuity as it really is.

As our crowdfunding campaign enters its final days, this gives a real sense of the people, culture and ambition behind the PM1, AX1 and our wider Oculomics platform.

https://zurl.co/hcpqQ

15/12/2025

Over the weekend we passed our £1.1 million target on Republic and welcomed our 300th investor into the Occuity community. Thank you to everyone who has supported the campaign so far.

Hitting our target triggered the official 7 day countdown. This means the round will officially close at 12midnight on Friday 19th December. Once this window closes, the round will end.

If you’ve been following our progress and are considering joining us, now is the moment. With momentum building, major milestones achieved in the lab, and strong interest in our PM1, AX1 and Oculomics roadmap, we believe the future for Occuity has never looked more exciting. As the next round is very likely to be an institutional Series A raise, this will be your last chance to invest in Occuity.

Five days to go. Don’t miss your chance to be part of what comes next.
https://zurl.co/ieqmb

10/12/2025

We passed £1million in our current raise on Republic at the start of the week!

More than 280 investors have now joined us on our mission to transform disease screening and diagnostics using the eye as a window to the health of the body.

Reaching £1 million is a powerful validation of our technology, our team and confidence in our long-term Oculomics strategy. It reflects the growing belief that handheld, non-contact optical devices like the PM1 and AX1 can reshape global healthcare — and that Occuity is the company to deliver that change.

We’re getting closer to our £1.1million target and the campaign will be closing soon.

03/12/2025

Last week, our team achieved a major milestone: a world-first in vivo retinal imaging result using brand-new, non-invasive optical methods developed in our Reading labs.

This breakthrough allows us to distinguish different molecules in the retina in vivo with unprecedented precision — a step that could reshape early detection of both ocular and systemic disease. It’s a huge moment for our Future Leaders Fellowship programme and a powerful validation of the technology we’re building.

(It's frustrating that we cant share more than this, but our team are currently working on patent applications.)

👉 Join us tonight for a webinar, where our Head of Marketing, Richard Kadri-Langford will host a panel discussion with our Senior Leadership team.

If you’re interested in the future of eye-based diagnostics, early disease detection, or investing in high-impact MedTech, this is one you won’t want to miss.

🔗 Register here: https://zurl.co/Qb4ML

Unprecedented In Vivo Retinal Imaging Achieved in Occuity’s Reading Labs

27/11/2025

Have you heard about Occuity and want to understand more about what we do - and where we’re headed? Join us for a special live Q&A Webinar with the leadership team.

This is your chance to explore our technology, ask the questions that matter to you, and understand how we plan to bring our vision to life.

We’ll talk about:
• How our optical platform works
• The products we’re launching now (like the AX1)
• Our long-term ambitions — including diabetes and Alzheimer’s screening
• What investing in Occuity means

Whether you’re already interested, curious, or just looking to learn — we’d love to have you with us.

👉 Learn more and register: https://zurl.co/Wp0gs

See you there — and bring your questions!

We’re excited to invite you to a very special webinar on Wednesday 3rd December 8pm Rather than delivering another standard presentation, we wanted to do something different.

25/11/2025

Last week, our CEO Dan Daly and CCO Mark Jenkins joined Jonathan Roy on the UK Investor Magazine Podcast for a deep dive into Occuity’s mission, technology and progress.

It’s a really insightful conversation covering:

• How we’re using the eye as a window into the health of the body
• The journey from founding Occuity in 2019 to launching our first devices
• The growing global need for non-invasive screening tools
• Our work in myopia management, glaucoma, diabetes and Alzheimer’s
• The vision behind our optical technology platform

If you’re interested in where the future of eye-based health screening is heading, this episode is well worth a listen.

🎧 Listen here:
👉 https://zurl.co/rcxnP

If you have any questions or want to know more about what we’re building, feel free to get in touch.